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BACKGROUND: Klepsiella pneumoniae, one of clinical  isolates, is frequently found causative agent of hospital acquired infection. Currently, K. 
pneumoniae  is  found  as extended-Spectrum β-lactamases 
(ESBL)  producer,  allowing  it  to  become  multidrug-
resistant.  A  clinical  laboratory  with  limited  facility  needs 
a  valid,  reliable,  inexpensive  and  simple  laboratory  test 
to  control  its  infection  and  antimicrobial-resistancy. 
The aim  of  this  study  is  to  evaluate  the  diagnostic 
performance  of  a  ESBL  media  to  detect  ESBL-producing 
K.  pneumoniae.  
METHODS: An independent and blind comparative study 
of ChromID ESBL media and Double Disc Synergy Test 
(DDST) was conducted for detecting the clinical isolate of 
ESBL-producing K. pneumoniae. Clinical isolates of K. 
pneumoniae collected from the Clinical Laboratory of Dr. 
Sardjito Hospital were isolated. 
RESULTS: There were 103 clinical isolates of K. 
pneumoniae,  which  were  isolated  from  urine,  pus, 
blood,  stool,  cerebrospinal  fluid,  sputum, drain  liquid, 
nasal  sinus  liquid,  gastric  wash,  bronchi liquid, injury 
liquid  and nasal swab. The number of true positive, true 
negative, false  positive  and  false  negative  results  were 
74, 18, 9 and 2, respectively. Meanwhile, the sensitivity, 
specificity, positive predictive  value,  negative  predictive 
value,  likelihood  ratio  for  positive  result  and  likelihood 
ratio  for  negative  result  of  the  new  ESBL  media  were 
97.4%,  66.7%,  89.2%,  90%,  2.9  and  0.03,  respectively. 
CONCLUSION: Since the new ESBL media and DDST 
results were similar, so the new ESBL media could be 
used for screening patients with clinical presentation that 
indicating a high suspicious of ESBL-producing bacteria. 
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Abstract
Introduction
In developing countries, infectious diseases remain as 
the first cause of illness in community. Treatments for 
infections usually involve antibiotics. With many advances 
in technology, the number and type of clinically useful 
antibiotics is increasing. Inappropriate antibiotic treatment 
may result adverse effects, such as the emergence of 
bacterial resistance and low antibiotic efficacy against 
certain bacteria. Bacterial resistance against antibiotics are 
a current global issue.(1)
 Resistance against antibiotics is mostly caused 
by nosocomial infections. Klebsiella spp. are important 
pathogenic bacteria causing nosocomial infections. 
Generally, Klebsiella spp. infections are implicated in 
pneumonia, urinary tractus infections, meningitis and 
septicemia. The increasing resistancy of Klebsiella 
spp. has been widely reported as the effect of enzymes 
extended-spectrum β-lactamases (ESBL) and Klebsiella 
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pneumoniae carbapenemase (KCP).(2) ESBL is an enzyme 
that hydrolyze penicillin, cephalosporin (first, second, third 
generations), oxymino-β-lactam compound (aztreonam, 
but not cephamycin and carbapenem) and may be inhibited 
by β-lactamase inhibitor (clavulanate, sulbactam and 
tazobactam).(3)
 Various screening and confirmation tests have been 
developed to detect ESBL-producing K. pneumoniae. 
However, the increasing diversity of  ESBL-producing K. 
pneumoniae strains, along with resistance mechanism of 
non-ESBL-producing  K. pneumoniae,  making identification 
of ESBL-producing K. pneumoniae by conventional 
phenotypic techniques difficult.(4) Double Disc Synergy 
Test (DDST) is able to find the phenotypic character profile 
of ESBL resistance against third generation cephalosporin 
(ceftazidim, cefpodoxime, ceftriaxone) and monobactams 
(aztreonam). The presence of ESBL-producing  bacteria  was 
indicated  by  an  increase in inhibitory zone on amoxicillin/
clavulanic acid through third-generation cephalosporins.(5)
 There was a breakthrough in the development 
of selective chromogenic medium for the screening of 
ESBL-producing K. pneumoniae directly from clinical 
specimens. Selectivity was provided based on colony 
color by chromogenic media.(6) New ESBL media with 
chromogenic medium has been developed. It contains 
nutrient rich  media with a mixture of antibiotics, including 
cefpodoxime for detection of ESBL-bearing bacteria.(7) A 
study reported that the new ESBL media had a sensitivity of 
88% and specificity of 94.4% in detecting ESBL-producing 
Enterobactericeae in 24 hours.(8)
 In detecting antimicrobial resistance, the role of 
routine laboratory services is very essential. Surveillance 
of bacterial pattern, antibiogram pattern, multiresistant 
bacterial detection is an important support for the treatment 
of patients with infections and reasonable antibiotic 
prescription. The objective of the study is to evaluate the 
sensitivity of new ESBL media with chromogenic medium 
in detecting ESBL-producing K. pneumoniae.
Methods
confirmatory test (9) and has sensitivity  of 91.3% and 
specificity of 100%.(10)
 The clinical isolates of K. pneumoniae were obtained 
from urine, pus, blood, feces, sputum, cerebrospinal fluid, 
drain  liquid,  nasal  sinus  liquid,  gastric  wash,  bronchi 
liquid, injury liquid  and nasal swab. The clinical samples 
were inoculated on the appropriate media. After the 
growth was detected, identification of K. pneumoniae was 
performed using Vitek 2 System (bioMérieux). 
 The identified isolates of K. pneumoniae were 
inoculated on the ESBL media and incubated at 35°C for 
18-24 hours, followed by observation and interpration. 
The growth of green colonies were interpretated as ESBL-
producing K. pneumoniae. 
 DDST was performed by inoculating 0.5 McFarland 
turbidity standard of K. pneumoniae suspension on the 
Mueller Hinton solid media plate. After the suspension was 
dried, 30 µg ceftazidim, 30 µg cefotaxime, 30 µg cefepime 
and 20/10µg amoxycillin/clavulanic acid disc were added on 
the media. The media plates were incubated at 35°C for 18-
24 hours. The presence/absence of an increase in inhibitory 
zone between β-lactam discs and β-lactam/β-lactamase 
inhibitor disc can be observed after the incubation. 
 K. pneumoniae ATCC 7000603  was  used  as  the 
positive  control  of  ESBL-producing bacteria, whereas 
Escherichia coli ATCC 25922 was used as the negative 
control of non-ESBL-producing bacteria. The results of 
ESBL media and DDST were intepreted by two observers.
 The collected data were analyzed using decriptive 
statistic. Diagnostic performance was evaluated using 
2x2 table. The  sensitivity, specificity, accuracy, positive 
predictive value, negative predictive value, positive 
likelihood ratio and negative likelihood ratio were 
determined with 95% confidence interval.
 The study was conducted in Clinical Laboratory of 
Dr. Sardjito Hospital Yogyakarta, Indonesia started from 
July to September 2015. Ethical clearance was issued by 
the Medical and Health Research Ethics Committee Faculty 
of Medicine, University of Gadjah Mada, Yogyakarta, 
Indonesia No. KE/KF/868/EC/2015.
ResultsA diagnostic test study using 103 clinical isolates of K. 
pneumoniae was conducted. In this study, the ChromID® 
ESBL media (bioMérieux, Marcy-l'Étoile, France) was used 
as the new ESBL media with chromogenic medium. The 
ESBL media was independently  and  blindly  compared 
to the DDST, the gold standard test in detecting ESBL-
producing K. pneumoniae. DDST is known as one of the 
Total number of  K. pneumoniae isolates were 103, collected 
from patients with different ages, as shown in Table 1. 
Sources of isolates were mostly urine (29.1%), pus (28.2%) 
and blood (22.3%). Urine specimens were collected from 
patients diagnosed with urinary tractus infection, chronic 
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Table 1. Characteristics of sources of clinical isolates.  Result of new ESBL media and DDST were shown 
in Table 2. DDST was able to detect 76 isolates of ESBL-
producing K. pneumoniae (73.8%), whereas the ChromID® 
ESBL media was able to detect 83 isolates of ESBL-
producing K. pneumoniae (80.6%). By using DDST as the 
standard, there were 9 samples with false positive and 2 
samples with false negative results of new ESBL media. 
 Table 3 showed the test characteristic of ChromID 
ESBL media in detecting the ESBL-producing K. 
pneumoniae. New ESBL media had high sensitivity 




Toddlers (<5 years) 34 33
Child (≥5 - <18 years) 10 9.7
Adults (≥18 - <55 years) 32 31.1





Cerebrospinal fluid 2 1.9
Sputum 1 1.0
Stool 1 1.0
Drain liquid 1 1.0
Nasal sinus liquid 1 1.0
Gastric  wash 1 1.0
Bronchi liquid 1 1.0
Injury liquid 1 1.0
Nasal swab 1 1.0
Types of clinical care
Intensive 19 18.5
Non-intensive: - Surgical 9 8.7





Number of isolates 
ESBL (+) ESBL (-)
ChromID® ESBL Test ESBL (+) 74 9 83




Table 2. Comparison between ChromID ESBL media and DDST.
renal failure, acute renal failure and kidney stones. Pus 
specimens were collected from patients diagnosed with 
diabetic ulcers, mandibula abscess, post laparotomy, colon 
abscess and nasal cavity carcinoma. The patients were 
mostly from non-intensive care without surgical treatment 
(59.2%). Meanwhile, 18.5% of patients were taken care 
in intensive care unit. Detail characteristics of isolates 
regarding age, source of isolates and their respective ward 
were shown in Table 1.
Discussion
In this study, study subjects catagorized as elderly (≥ 55 years 
old) was 26.2%. Meanwhile previous study in hemodialysis 
patients whom suffered from bacteremia caused by K. 
pneumoniae reported that the proportion of patients older 
than 65 years old was 57.8%.(11)  Another study reported 
that majority of study subjects (54.2%) whom suffered from 
K. pneumoniae bloodstream infections were aged more than 
60 years.(12)
 Most of subjects in this study (68%) were from non-
intensive care unit and only 18.5% were from the intensive 
care unit. A study in hemodialysis patients who also suffered 
from K. pneumoniae bacteremia, reported that 46.7% of 
subjects were from the intensive care unit. Another study 
reported that 67.9% of hospital-acquired K. pneumoniae 
infections were particularly among patients from neonatal 
intensive care unit, with mortality rate up to 70%.(13) 
 Reglier-Poupet stated that longer incubation period of 
new ESBL media test may improve the sensitivity of this 
test. Negative results obtained from the new ESBL media 
can be improved with longer incubation. Incubation for 24 
hours was associated with sensitivity of 88% and specificity 
of 94.4%. Meanwhile, incubation for 48 hours resulted in 
sensitivity of 94% and specificity of 90.5%. In the new 
ESBL media test with a reincubation period for 48 hours, 
colonies still did not grow, indicating no ESBL-producing 
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Table 3. Test characteristic of ChromID ESBL.
Value 95% CI
Sensitivity (%) 97.4 90.82 - 99.68
Specificity (%) 66.7 46.04 - 83.48
Positive Predictive Value (%) 89.2 80.35 - 94.95
Negative predictive value (%) 90 68.30 - 98.77
Positive Likelihood Ratio 2.9 1.71 - 4.99
Negative Likelihood Ratio 0.03 0.01 - 0.16
study reported that the new ESBL meda test had sensitivity 
of 94.9% and specificity of 94.9% in detecting ESBL-
producing Enterobactericeae.(16)
Conclusion
The new ESBL media and DDST results were similar. The 
sensitivity, specificity, positive predictive value and negative 
predictive value of the new ESBL media were appropriate. 
Therefore, it could be used for for screening patients with 
clinical presentation that indicating a high suspicious of 
ESBL-producing bacteria. All suspected ESBL-producing 
bacteria that were tested with the new ESBL media should 
be confirmed with a confirmation test, such as DDST.
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